Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

InnoCare receives NMPA clearance for phase II study of orelabrutinib in ITP

Aug. 11, 2021

China's NMPA approves IND for phase I/II study of BBM-H901

Aug. 11, 2021

Positive interim data presented from phase I study of FTX-6058

Aug. 11, 2021

KV-998083 effective in models of thrombosis and vascular leakage

July 30, 2021

First-in-human study investigates HJV inhibitor DISC-0974 for anemia of inflammation

July 28, 2021

FXa-DOAC reversal with no thrombogenic potential seen with VMX-C001

July 28, 2021

ExCellThera initiates phase I study of ECT-001-CB in sickle cell disease

July 23, 2021

Chinese researchers patent coagulation factor XIa inhibitors

July 23, 2021

FDA places clinical hold on phase I/II study of SIG-001 in hemophilia A

July 12, 2021

FDA clears IND for ASC-618 gene therapy for hemophilia A

July 8, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...